Overview
Serap Yalcin practices practicing medicine in Kirsehir, Turkey.
Their clinical expertise encompasses Familial Colorectal Cancer, Breast Cancer, and Triple-Negative Breast Cancer.
They are actively involved in clinical research, co-authoring 22 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Serap Yalcin
Is Serap Yalcin a top-rated expert for Familial Colorectal Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Serap Yalcin is classified as an Experienced expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Serap Yalcin participate in research or clinical trials?
Yes. Serap Yalcin has published 22 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Serap Yalcin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerYalcin isExperienced. Learn about Breast Cancer.
- Familial Colorectal CancerYalcin isExperienced. Learn about Familial Colorectal Cancer.
- Triple-Negative Breast CancerYalcin isExperienced. Learn about Triple-Negative Breast Cancer.